We bring you the latest news from the healthcare about the health care in the United Kingdom.

woensdag 17 oktober 2018

The Lancet: [Comment] IGF-1 for spinal and bulbar muscular atrophy: hope and challenges

[Comment] IGF-1 for spinal and bulbar muscular atrophy: hope and challenges
Spinal and bulbar muscular atrophy, also known as Kennedy disease, is an adult-onset, hereditary neuromuscular disease characterised by weakness, contraction fasciculations, and bulbar involvement.1 Spinal and bulbar muscular atrophy exclusively manifests in men, and the prevalence of this disease is estimated to be about one to two per 100 000 people worldwide. The progression of neurological deficits is usually slow, with an average interval of 20 years between the onset of weakness and death, which often results from aspiration due to bulbar palsy.
Read more

[In Context] Memory is composed "with a grace of its own"
On the surface, human memory might seem like a simple thing, a record of everything a person has seen or heard or read, no different to a video camera; but it is not objective. Instead, it is highly prone to lapses and distortion, its value as an objective record of events distorted by subjectivity. This contradiction lies at the heart of research in the field of learning and memory, which walks a fine line between the objective realm of experimental data and the subjective world of lived experience.
Read more

[In Context] Argentina's unanswered stroke health-care question
Stroke prevention is on the medical agenda in Argentina. Improving stroke recognition and treatment is too. But if health-care coverage for stroke remains far from universal, won't the impact of any progress be necessarily reduced? Adrian Burton investigates.
Read more

[Comment] Optimal stroke prevention in patients with patent foramen ovale
A substantial proportion of patients with ischaemic stroke present with embolic stroke of undetermined source (ESUS), which is associated with a considerable rate of recurrence. The NAVIGATE ESUS trial1 aimed to compare the safety and efficacy of oral anticoagulation (rivaroxaban, a factor Xa antagonist) with antiplatelet therapy (aspirin) for secondary stroke prevention in patients with ESUS. The trial randomly assigned 7213 patients with a recent stroke to receive rivaroxaban 15 mg or aspirin 100 mg daily.
Read more

[In Context] Adventures in Slumberland
In 1880, the French physician Jean-Baptiste-Édouard Gélineau described a 38-year-old man with severe bouts of sleepiness and episodes of muscle weakness when laughing out loud or anticipating a good business deal. Gélineau proposed the name narcolepsy, from the Greek narcosis (drowsiness) and lambanein (to take or to seize), to describe the patient's condition. More than 100 years later, Henry Nicholls walked into the National Hospital for Neurology and Neurosurgery in London, UK. He was accompanied by his best friend, whose job was to "wait until [Henry] was wired up and the cameras were rolling, then make [him] fall over laughing", thereby inducing fits of paralysis and confirming the diagnosis of narcolepsy.
Read more